Literature DB >> 14551156

Anoikis in the cardiovascular system: known and unknown extracellular mediators.

Jean-Baptiste Michel1.   

Abstract

Anoïkis is defined as programmed cell death induced by the loss of cell/matrix interactions. Adhesion to structural glycoproteins of the extracellular matrix is necessary for survival of the differentiated adherent cells in the cardiovascular system, including endothelial cells, smooth muscle cells, fibroblasts, and cardiac myocytes. Adhesion is also a key factor for the differentiation of mesenchymal stem cells. In particular, fibronectin is considered a factor of survival and differentiation for many adherent cells. Adhesion generates cell tensional integrity (tensegrity) and repression of apoptotic signals, whereas detachment has the opposite effect. Anoïkis plays a physiological role by regulating cell homeostasis in tissues. However, anoïkis can also be involved in pathological processes, as illustrated by the resistance to anoïkis in cancer and its enhancement in degenerative tissue remodeling. Extracellular mediators of anoïkis include matrix retraction, leading to loss of tensegrity in fibroblasts, pharmacological disengagement of integrins by RGD-like peptides and fragments of fibronectin, and focal adhesion disassembly by fragments of thrombospondin, plasminogen activator-1, and high-molecular-weight kininogen. In addition to binding of the RGD peptide by integrins, the engagement of the heparin binding sites of adhesive glycoproteins with glycosaminoglycans on the cell surface is also involved in the prevention of cell detachment-induced apoptosis. Proteases able to degrade adhesive glycoproteins, such as fibronectin, induce anoïkis of vascular adherent cells. Active proteases can either be secreted directly by inflammatory cells, as elastase and cathepsin G by polymorphonuclear leukocytes, chymase and tryptase by mast cells, and granzymes by lymphocytes, or generated from circulating zymogens by activation in close contact with the cells. This is the case for the pericellular conversion of plasminogen to plasmin, which degrades fibronectin and induces anoïkis of smooth muscle cells. Involvement of proteases has also been proposed in the apoptotic response of cultured adherent cells to serum starvation. Anoïkis is probably involved in pathological remodeling of cardiovascular tissues, including cardiac myocyte detachment in heart failure, deendothelialization and plaque rupture in atherosclerosis, and smooth muscle cell disappearance in aneurysms and varicose veins. The absence of cell adhesion and growth resulting from cleavage of adhesive proteins also represents a major impediment to cellular healing, including the absence of cell recolonization of proteolytically injured tissue and the low efficacy of cell transplantation. However, the exact role of anoïkis in cardiovascular pathologies remains to be further defined.

Entities:  

Mesh:

Year:  2003        PMID: 14551156     DOI: 10.1161/01.ATV.0000099882.52647.E4

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  79 in total

1.  Cardiomyocytes in vitro adhesion is actively influenced by biomimetic synthetic peptides for cardiac tissue engineering.

Authors:  Alessandro Gandaglia; Rocio Huerta-Cantillo; Marina Comisso; Roberta Danesin; Francesca Ghezzo; Filippo Naso; Alessandra Gastaldello; Eleonora Schittullo; Edward Buratto; Michele Spina; Gino Gerosa; Monica Dettin
Journal:  Tissue Eng Part A       Date:  2011-12-05       Impact factor: 3.845

Review 2.  Using biomaterials to improve the efficacy of cell therapy following acute myocardial infarction.

Authors:  Jay H Traverse
Journal:  J Cardiovasc Transl Res       Date:  2011-11-17       Impact factor: 4.132

3.  Differential responses of induced pluripotent stem cell-derived cardiomyocytes to anisotropic strain depends on disease status.

Authors:  Young Wook Chun; David E Voyles; Rutwik Rath; Lucas H Hofmeister; Timothy C Boire; Henry Wilcox; Jae Han Lee; Leon M Bellan; Charles C Hong; Hak-Joon Sung
Journal:  J Biomech       Date:  2015-10-08       Impact factor: 2.712

4.  Combinatorial activation of FAK and AKT by transforming growth factor-beta1 confers an anoikis-resistant phenotype to myofibroblasts.

Authors:  Jeffrey C Horowitz; David S Rogers; Vishal Sharma; Ragini Vittal; Eric S White; Zongbin Cui; Victor J Thannickal
Journal:  Cell Signal       Date:  2006-11-17       Impact factor: 4.315

Review 5.  Death and inflammation following somatic cell transplantation.

Authors:  Ian B Copland; Jacques Galipeau
Journal:  Semin Immunopathol       Date:  2011-05-01       Impact factor: 9.623

6.  A synthetic substrate to support early mesodermal differentiation of human embryonic stem cells.

Authors:  Yang Liu; Xintong Wang; Dan S Kaufman; Wei Shen
Journal:  Biomaterials       Date:  2011-08-06       Impact factor: 12.479

7.  The Mef2A transcription factor coordinately regulates a costamere gene program in cardiac muscle.

Authors:  Elizabeth P Ewen; Christine M Snyder; Megan Wilson; Danielle Desjardins; Francisco J Naya
Journal:  J Biol Chem       Date:  2011-07-01       Impact factor: 5.157

Review 8.  Can the outcomes of mesenchymal stem cell-based therapy for myocardial infarction be improved? Providing weapons and armour to cells.

Authors:  Andrey A Karpov; Daria V Udalova; Michael G Pliss; Michael M Galagudza
Journal:  Cell Prolif       Date:  2016-11-23       Impact factor: 6.831

9.  Loss of Elastic Fiber Integrity Compromises Common Carotid Artery Function: Implications for Vascular Aging.

Authors:  J Ferruzzi; M R Bersi; R P Mecham; F Ramirez; H Yanagisawa; G Tellides; J D Humphrey
Journal:  Artery Res       Date:  2016-04-22       Impact factor: 0.597

Review 10.  Calreticulin: non-endoplasmic reticulum functions in physiology and disease.

Authors:  Leslie I Gold; Paul Eggleton; Mariya T Sweetwyne; Lauren B Van Duyn; Matthew R Greives; Sara-Megumi Naylor; Marek Michalak; Joanne E Murphy-Ullrich
Journal:  FASEB J       Date:  2009-11-25       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.